Ligand Pharmaceuticals, Inc.
LGNXZ
Other OTC0.00
USD
+0.00
- -
CIK
0000886163
ISIN
US53220K1815
CUSIP
53220K181
Return %
Stock
S&P500
1Y
- -
18.21
3Y
81.82
63.29
5Y
-89.19
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Todd C. Davis
- Full Time Employees
- 47
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 555 Heritage Drive Jupiter FL United States of America 33458
- IPO Date
- Nov 1, 2022
- CIK
- 0000886163
- Website
- ligand.com
- Similar Companies
- Business
- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) operates as a biopharmaceutical company focused on acquiring, developing, and monetizing royalty-generating assets and technology platforms for drug development and commercialization. Founded in 1987 and headquartered in San Diego, California, the company manages one of the industry's largest and most diverse portfolios of biopharmaceutical royalties, encompassing more than 90 partnered commercial and development-stage programs across oncology, kidney disease, diabetes, nonalcoholic steatohepatitis, and rare conditions; these include royalties from Kyprolis and Evomela for multiple myeloma, Filspari for kidney disease, Vaxneuvance for pneumococcal disease, Rylaze for acute lymphoblastic leukemia, Tzield for type 1 diabetes, Teriparatide injection for osteoporosis, and Zelsuvmi for molluscum contagiosum, with products marketed in over 70 countries. Ligand maintains and licenses its proprietary Captisol and NITRICIL technology platforms to a broad network of biopharmaceutical partners, including Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International, enabling improved drug formulations and delivery across various therapeutic areas. The company serves global pharmaceutical and biotech firms through royalty aggregation, financing for clinical development and commercialization, and technology licensing, with operations spanning the United States, Europe, and international markets via its partners. Recent developments include the July 2025 completion of the merger between its subsidiary Pelthos Therapeutics and Channel Therapeutics, forming Pelthos Therapeutics Inc. (NYSE American: PTHS), which launched ZELSUVMI for molluscum contagiosum and entitles Ligand to a 13% royalty on worldwide sales; a $70 million investment with Medtronic in Orchestra BioMed to advance late-stage cardiology programs AVIM therapy and Virtue SAB; a $75 million financing in Castle Creek Biosciences for its D-Fi program targeting dystrophic epidermolysis bullosa, providing Ligand a high-single-digit royalty; the July 2024 acquisition of APEIRON Biologics for $100 million plus a $4 million investment in its spin-off invIOs; the pricing of $400 million in convertible senior notes due 2030; an expanded credit facility from $75 million to $125 million; and strong 2025 financial performance with Q3 revenue of $115.5 million, up 123% year-over-year, alongside raised full-year guidance.